Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study


23 Nov 2019


Poster display session


Tumour Site

Colon and Rectal Cancer


JianWei Zhang


Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421


J. Zhang, Y. Deng

Author affiliations

  • Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, 510655 - Guangzhou/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 81P


mFOLFOX6 concurrent radiotherapy in the FOWARC study led to 27% of pCR rate in locally advanced rectal cancer (LARC). The total neoadjuvant treatment study (CAO/ARO/AIO-12) had compared the efficacy of chemoradiotherapy plus induction or consolidation chemotherapy. The result showed that consolidation chemotherapy led to higher pCR rate than that of induction chemotherapy. Here, we aimed to compare the efficacy of preoperative concurrent mFOLFOX6 chemoradiotherapy versus concurrent and consolidation chemotherapy during radiation as neoadjuvant treatment in locally advanced rectal cancer.


Prospectively maintained databases of patients from two clinical trials ( NCT01211210 and NCT02217020) underwent preoperative treatment for locally advanced rectal cancer were included. 143 patients received concurrent mFOLFOX6 chemoradiotherapy and TME surgery. 123 patients received concurrent and consolidation chemotherapy during radiation before TME. A comparative analysis was performed after the implementation of propensity score matching on the 2 main cohorts.


A total of 266 patients were enrolled in the study. After propensity score matching, 180 patients were selected. 113 patients were comparable in the two groups. The pathologic complete response rate was comparable between the two groups (27.1% vs. 27.9%). And the tumor downstaging rate was also similar between the two groups (54.1vs. 59.1%). The compliance of chemotherapy was much better in concurrent chemoradiotherapy with mFOLFOX6 (93.5% vs. 39.5%). Higher incidence of grade 3/4neutropenia (16.1% vs. 30.1%, P < 0.01) was shown in concurrent chemoradiotherapy group than that of concurrent and consolidation chemoradiotherapy group.


Preoperative concurrent chemoradiotherapy with mFOLFOX6 showed similar efficacy with radiotherapy plus consolidation chemotherapy and higher compliance of chemotherapy. Long-term follow-up will assess whether the higher compliance would translates to better oncologic outcome.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Yanhong Deng.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.